ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Iterum Therapeutics PLC

Iterum Therapeutics PLC (ITRM)

1.53
0.03
( 2.00% )
Actualizado: 10:04:40

Herramientas de nivel profesional para inversores individuales.

Estadísticas y detalles clave

Último Precio
1.53
Postura de Compra
1.52
Postura de Venta
1.54
Volume Operado de la Acción
114,544
1.51 Rango del Día 1.54
0.808 Rango de 52 semanas 3.02
Capitalización de Mercado [m]
Precio Anterior
1.50
Precio de Apertura
1.52
Última hora de negociación
10:04:40
Volumen financiero
US$ 174,291
Precio Promedio Ponderado
1.5216
Volumen promedio (3 m)
1,046,664
Acciones en circulación
27,515,926
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-1.09
Beneficio por acción (BPA)
-1.39
turnover
82k
Beneficio neto
-38.37M

Acerca de Iterum Therapeutics PLC

Iterum Therapeutics PLC is a pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance ... Iterum Therapeutics PLC is a pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
Sede
Chicago, Illinois, USA
Fundado
-
Iterum Therapeutics PLC is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ITRM. The last closing price for Iterum Therapeutics was US$1.50. Over the last year, Iterum Therapeutics shares have traded in a share price range of US$ 0.808 to US$ 3.02.

Iterum Therapeutics currently has 27,515,926 shares in issue. The market capitalisation of Iterum Therapeutics is US$41.27 million. Iterum Therapeutics has a price to earnings ratio (PE ratio) of -1.09.

ITRM Últimas noticias

Iterum Therapeutics Regains Full Nasdaq Compliance

DUBLIN and CHICAGO, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), (the Company), a company focused on delivering next generation oral and IV antibiotics to treat...

Iterum Therapeutics Reports Third Quarter 2024 Financial Results

-- ORLYNVAHTM Approved by FDA on October 25, 2024— --Company to Host Conference Call Today at 8:30 a.m. EDT-- DUBLIN and CHICAGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc...

Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

DUBLIN and CHICAGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1001.531.57991.464935261.49940455CS
4-0.25-14.04494382021.782.11.465452561.65247947CS
120.2822.41.253.021.2110466641.92416047CS
260.3529.66101694921.183.020.80816541511.75266936CS
52-0.77-33.47826086962.33.020.80810336871.7094443CS
1561.2003364.0582347590.32973.13050.1758741770.9383906CS
260-1.12-42.26415094342.656.020.17536383521.35441318CS

ITRM - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Iterum Therapeutics?
El precio actual de las acciones de Iterum Therapeutics es US$ 1.53
¿Cuántas acciones de Iterum Therapeutics están en circulación?
Iterum Therapeutics tiene 27,515,926 acciones en circulación
¿Cuál es la capitalización de mercado de Iterum Therapeutics?
La capitalización de mercado de Iterum Therapeutics es USD 41.27M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Iterum Therapeutics?
Iterum Therapeutics ha negociado en un rango de US$ 0.808 a US$ 3.02 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Iterum Therapeutics?
El ratio precio/beneficio de Iterum Therapeutics es -1.09
¿Cuál es el ratio de efectivo a ventas de Iterum Therapeutics?
El ratio de efectivo a ventas de Iterum Therapeutics es 506.67
¿Cuál es la moneda de reporte de Iterum Therapeutics?
Iterum Therapeutics presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Iterum Therapeutics?
El último ingresos anual de Iterum Therapeutics es USD 82k
¿Cuál es el último beneficio anual de Iterum Therapeutics?
El último beneficio anual de Iterum Therapeutics es USD -38.37M
¿Cuál es la dirección registrada de Iterum Therapeutics?
La dirección registrada de Iterum Therapeutics es 200 S WACKER DRIVE, SUITE 650, CHICAGO, ILLINOIS, IL 60606
¿Cuál es la dirección del sitio web de Iterum Therapeutics?
La dirección del sitio web de Iterum Therapeutics es www.iterumtx.com
¿En qué sector industrial opera Iterum Therapeutics?
Iterum Therapeutics opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
FOXXFoxx Development Holdings Inc
US$ 8.0512
(178.59%)
10.82M
AMODAlpha Modus Holdings Inc
US$ 4.1517
(169.59%)
82.94M
TECXTectonic Therapeutic Inc
US$ 56.94
(121.38%)
3.58M
KZIAKazia Therapeutics Ltd
US$ 2.06
(49.28%)
88.12M
ACONAclarion Inc
US$ 13.53
(46.87%)
204.5k
CLEUChina Liberal Education Holdings Ltd
US$ 0.61
(-92.13%)
66.19M
CRGXCARGO Therapeutics Inc
US$ 3.055
(-76.84%)
11.58M
FATFAT Brands Inc
US$ 3.405
(-41.99%)
136.12k
IRWDIronwood Pharmaceuticals Inc
US$ 2.345
(-36.96%)
4.03M
KRKR36Kr Holdings Inc
US$ 6.1525
(-34.69%)
529.6k
NVDANVIDIA Corporation
US$ 119.06
(-3.75%)
134.43M
MGOLMGO Global Inc
US$ 0.1295
(27.34%)
128M
SPGCSacks Parente Golf Inc
US$ 0.78075
(32.33%)
94.96M
KZIAKazia Therapeutics Ltd
US$ 2.05
(48.55%)
89.43M
AMODAlpha Modus Holdings Inc
US$ 4.17
(170.78%)
84.1M

ITRM Discussion

Ver más
Klinsmann Klinsmann 2 meses hace
Huh? Whatever you say... 
this stock is primed for a huge breakout soon. Chart beauty, and buyout news is just pending. They won't sell such a premium product for chump change. 
👍️ 1 🥳 1
KIPK KIPK 2 meses hace
With EX pumping here ITRM will follow OTLK imo
👍️0
Klinsmann Klinsmann 2 meses hace
100%! The approved drug is worth 300-500 million, and maybe this is even a conservative figure. Just look at the market cap and connect the dots... Have a nice weekend
👍️ 1 🤩 1
glenn1919 glenn1919 2 meses hace
ITRM....................https://stockcharts.com/h-sc/ui?s=ITRM&p=W&b=5&g=0&id=p86431144783
👍️0
 just Scottie just Scottie 2 meses hace
Ya think it can really go that high?
👍️0
Klinsmann Klinsmann 2 meses hace
It depends. The fda approval makes this stock worth more than 10$. Not sure when book value and reality are going to match...
👍️0
TrendTrade2016 TrendTrade2016 2 meses hace
YEAH NO...BIT LATE SON EEARLY BIRD GETS THE WORM
👍️0
madras50 madras50 2 meses hace
there still time to jump on this or you think there is a pullback coming?
👍️0
TrendTrade2016 TrendTrade2016 2 meses hace
ITRM MONSTER
👍️0
glenn1919 glenn1919 2 meses hace
ITRM...................................https://stockcharts.com/h-sc/ui?s=ITRM&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 2 meses hace
ITRM BREAK OUT
👍 1
Klinsmann Klinsmann 2 meses hace
I know! And that could mean 15-20$. But most don´t even have the patience to hold until eow and are not able to stand a red day on the long way up and away...
👍️0
exwannabe exwannabe 2 meses hace
Not much patience needed. This will be likely be over before Spring.
👍️0
Klinsmann Klinsmann 2 meses hace
This stock is going to really bust! Most don't have that needed patience...
👍️0
TrendTrade2016 TrendTrade2016 2 meses hace
ITRM GAPPING AS WE APPROACH BREAK OUT...PLAY WITH CAUTION
👍️0
 just Scottie just Scottie 2 meses hace
If I’m not in a stock it busts out
If I’m in it tanks is my usual scenario
👍️0
Klinsmann Klinsmann 2 meses hace
In the end no matter what people on message boards say. The fundamentals in here are plain and simple great! I expect it to really astonish people soon - esp. when you're not in 😉
👍️0
TrendTrade2016 TrendTrade2016 2 meses hace
ITRM BREAK OUT PLAY FDA BIO MONTHS AGO
👍 1
exwannabe exwannabe 2 meses hace
Huh? No need to pump! FDA approval is a given fact!
Just ignore KIPK.

He is pissed off on another stock (NWBO, where he is banned on this board) about my negative posts. So he follows me around like a stalker and posts idiotic comments on any stock I discuss.
👍️ 1
Klinsmann Klinsmann 2 meses hace
Huh? No need to pump! FDA approval is a given fact!
👍️0
KIPK KIPK 2 meses hace
OTLK that EX been pumping just crashed; failed trial
👍️0
KIPK KIPK 2 meses hace
Beware of paid pumper/basher EX....................
👍️0
Klinsmann Klinsmann 2 meses hace
But the final number gonna be 5-10 times above our market cap rn around 2$...
👍️0
exwannabe exwannabe 2 meses hace
The game plan is to monetize by selling off either rights to the drug or the company. Either way all is over and all we can do is wait on the final number.
👍️0
 just Scottie just Scottie 2 meses hace
Sounds about right my friend
👍️ 1
Klinsmann Klinsmann 2 meses hace
Never left the boat! Added lows, no hurry to sell my shares. Expect 10$+
👍️0
 just Scottie just Scottie 2 meses hace
Where is everyone lol
A buyout is coming to town
👍️0
 just Scottie just Scottie 3 meses hace
Very important drug. Big pharma like Pfizer may come calling or has called already
👍️ 1
Klinsmann Klinsmann 3 meses hace
Gonna be a multi day run imo
👍️0
glenn1919 glenn1919 3 meses hace
ITRM..................https://stockcharts.com/h-sc/ui?s=ITRM&p=W&b=5&g=0&id=p86431144783
👍 1 🚀 1
 just Scottie just Scottie 3 meses hace
Excellent
👍 1 🚀 1
exwannabe exwannabe 3 meses hace
Label is about as expected. They did recommend culture testing (to insure proper agent is used for specific bug), bt did so in a general way that implies it is universal. No black box (was mentioned as possible to warn against creating resistence).
👍 1 💯 1
tw0122 tw0122 3 meses hace
Stuck in this halt but up 13% not  complaining 
1.40+ 20%
👍 1 🚀 1
 just Scottie just Scottie 3 meses hace
Agree
👍 1 🔥 1
tw0122 tw0122 3 meses hace
Big Pharma bribes, rules and runs the FDA its the American way of doing business meanwhiles urinary tract infection a big markets
👍 1 🚀 1
 just Scottie just Scottie 3 meses hace
Any strength shown is met with selling
👍️0
 just Scottie just Scottie 3 meses hace
Plus it’s not right to tie the company’s hands and restrict their ability to sell a product which will actually help people by having specific instructions on labels.

I tend to think if this was a big company such as Merck or Pfizer we wouldn’t have this issue
👍️0
 just Scottie just Scottie 3 meses hace
Yes it sounds like there will be some stipulations the FDA will enact.
It’s a shame! I understand the bug resistance aspect being in the medical field tho.

Im still a believer in the MD’S being the problem of which they don’t want to take full responsibility.
The FDA shouldn’t punish a biotech company for developing a new product which is needed. The AMA needs to do a better job of educating the educated 😆
👍️0
exwannabe exwannabe 3 meses hace
I went through the ADCOM material a few weeks ago, but mainly from the pov of understanding what the FDA analysis was. I am very comfortable the FDA is willing to bless sulo as being safe and effective, the only open question is how to try to restrict use to avoid resistance.

Replaying it and listening more closely to the details of the discussion of creating resistance, I can understand how this is a tough issue to tackle.

The proposed label by ITRM (designated susceptible micro-organisms) is clearly a non-starter. Nobody at the ADCOM could even say what that means, and even if they could, the family doc is not about to call for a several hundred dollar test just to prescribe a cheap pill that almost always "works". Alternatives such as use after failure or use for resistant bugs had no supportable data,. Certainly a problem for the FDA, but they will find some label that expresses the concern.

I would be certain they will exclude use as a step down following IV treatments. I suspect they will somehow say use for cases where the doctor finds treatment via augmenten is not suitable.

I would not at all be surprised to see the FDA go off the farm and issue a black box against abuse due to risk of generating carbo-penum resistant bugs.

I wold be certain there will be a REMS and/or post approval study on these issues.

On the broader issue of antibiotic management, I was encouraged everybody took it seriously. I was discouraged that most all felt the community docs will broadly ignore it and take the easy way out.

.
👍️0
 just Scottie just Scottie 3 meses hace
Yes! Cipro and augmentin have been around for a long time.
It will take a while for the bugs to become resistant to this one.
And yes the doctors are the ones that caused this over prescribing. They give it away like candy and use it as a prophylactic after just about every surgery
👍️0
exwannabe exwannabe 3 meses hace
For some explanation on that subject, the absurd off-label use of all antibiotics is a huge issue. That is true for all, nothing specific here. Go to most any third world or developing country and you can buy Cirpro for a few bucks for 2 weeks(?) worth, no prescription.

This is what is causing the problem with "super bugs". So yes, the FDA has a concern here.

OTOH, the same thing is why we need more choice in the field of antibiotics. And that is what this is, another choice for bugs that are are resistent to other antibiotics.
👍️0
 just Scottie just Scottie 3 meses hace
AI Overview
According to recent updates, the FDA appears to be leaning towards approving Sulopenem for the treatment of uncomplicated urinary tract infections (uUTIs), but with significant concerns regarding antimicrobial resistance and the need for careful monitoring through post-marketing surveillance to ensure appropriate usage; the FDA Advisory Committee acknowledged the potential benefit for a subset of patients while emphasizing the importance of managing off-label use and potential impact on antimicrobial resistance if approved.
👍️0
 just Scottie just Scottie 3 meses hace
Sounds like the drug works well. FDA has to have the appropriate usage on the label it sounds like
👍️0
exwannabe exwannabe 3 meses hace
Odds of approval are high, but I would not expect a huge gain.

Maybe up to $2-3 on thumbs up. Certainly down to almost $0 on thumbs down.

Again, I think the odds are good, so a good bet. Just think this is not one of those huge jumps you see on some drug approvals.
👍️0
 just Scottie just Scottie 3 meses hace
Any believers their drug gets approved Oct 25th?
Should fly if it does
👍️0
cervelo cervelo 4 meses hace
dang it should have run right after you sold
👍️0
velcro velcro 6 meses hace
No update or feedback, I dumped all shares
👍️0
velcro velcro 6 meses hace
Anyone understand the strategic planning behind the dilutive prospectus?
ITRM wants to raise cash now in the event the NDA Hearing is not good?
Or ITRM wants to raise cash now to hit the ground running with advertising after the successful NDA Hearing(s) in Sept and Oct.?
One indicator will be after subscription rights end 5 PM on August 6. Did investors jump on this or luke-warm maybe?
👍️0
velcro velcro 8 meses hace
Good News https://www.iterumtx.com/news/press-releases/detail/124/iterum-therapeutics-receives-fda-acceptance-of-resubmission
👍️0
glenn1919 glenn1919 8 meses hace
ITRM.......................https://stockcharts.com/h-sc/ui?s=ITRM&p=W&b=5&g=0&id=p86431144783
👍️0

Su Consulta Reciente

Delayed Upgrade Clock